Flutiair Special Precautions

General: Intranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Rarely, immediate hypersensitivity reactions or contact dermatitis may occur after the administration of Fluticasone Propionate (FLUTIAIR) Nasal Spray. Rare instances of wheezing, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure have been reported following the intranasal application of corticosteroids, including fluticasone propionate. Larger than recommended doses of Fluticasone Propionate (FLUTIAIR) Nasal Spray should be avoided. When used at higher than recommended doses or in rare individuals at recommended doses, systemic individuals at recommended doses, systemic corticosteroids effects such as hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of Fluticasone Propionate (FLUTIAIR) Nasal Spray should be discontinued slowly consistent with accepted procedures for discontinuing oral corticosteroid therapy.
Patient using Fluticasone Propionate (FLUTIAIR) Nasal Spray over several months or longer should be examined periodically for evidence of Candida infection or other signs of adverse effects on the nasal mucosa.
Special Precaution: Not for acute attacks. Caution when transferring patients from systemic steroid treatment. Avoid abrupt withdrawal. May unmask underlying eosinophilic conditions eg. Churg Strauss syndrome. Active or quiescent pulmonary TB.
Pregnancy. Monitor height of children for long-term treatment.